Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer

V. Westeel(Centre Hospitalier Universitaire de Besançon), B. Milleron, D. Debieuvre(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Denis Moro‐Sibilot(Centre Hospitalier Universitaire de Grenoble), A Depierre(National Cancer Centre Japan), M.A. Haller, Dominique Herman, Patrick Richard(Uniformed Services University of the Health Sciences), Marc Puyraveau, Maian Lev-El, Jean-Luc Breton, F.-X. Lebas, Élisabeth Quoix(GlaxoSmithKline (Italy)), M. Mercier
JNCI Journal of the National Cancer Institute
April 5, 2005
10.1093/jnci/dji096
Cited by 142

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
The Economic Costs of Pain in the United States
|Journal of Pain|2012|2.4k
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
|Journal of Clinical Oncology|1999|960
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
|The Lancet Respiratory Medicine|2019|937
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637